Aktis Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Aktis Oncology and other ETFs, options, and stocks.About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
CEOMatthew Roden
CEOMatthew Roden
Employees—
Employees—
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2020
Founded2020
Employees—
Employees—
AKTS Key Statistics
Market cap1.21B
Market cap1.21B
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume660.61K
Average volume660.61K
High today$23.18
High today$23.18
Low today$19.76
Low today$19.76
Open price$20.41
Open price$20.41
Volume186.49K
Volume186.49K
52 Week high$29.16
52 Week high$29.16
52 Week low$0.0372
52 Week low$0.0372
Stock Snapshot
As of today, Aktis Oncology(AKTS) shares are valued at $23.05. The company's market cap stands at 1.21B.
On 2026-01-22, Aktis Oncology(AKTS) stock moved within a range of $19.76 to $23.18. With shares now at $23.05, the stock is trading +16.6% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 186.49K, compared to an average daily volume of 660.61K.
The stock's 52-week range extends from a low of $0.04 to a high of $29.16.
The stock's 52-week range extends from a low of $0.04 to a high of $29.16.
People also own
Based on the portfolios of people who own AKTS. This list is generated using Robinhood data, and it’s not a recommendation.